Please assess the completion status of the following clinical trial:

Trial Title: Re-treatment of HCV Following DAA Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* participants with chronic HCV infection and viremia, who have completed the DAA-based standard treatment and relapsed~* regardless of severity of liver disease, HCV genotype, nature or duration of DAAs,and whether treatment-naïve or previously treated with Peg-IFN/ribavirin~Exclusion Criteria:~1. Participants with chronic kidney disease~2. Post-organ transplant recipients~3. Short life expectancy (\<1 year)~4. Not willing to follow-up~5. Individuals with immunocompromised states: HIV, immunosuppressive drugs, cancer chemotherapy, congenital hemolytic anemia

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sof+Ledi+R arm (Type: EXPERIMENTAL): Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination~1. Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~2. Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~3. Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon
- Sof+Ledi+R+Peg-IFN arm (Type: EXPERIMENTAL): Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
- Sof+Dacla+R arm (Type: EXPERIMENTAL): Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin~1. Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~2. Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~3. Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon
- Sof+Dacla+R+Peg-IFN arm (Type: EXPERIMENTAL): Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
- Sof+Velpa+R arm (Type: EXPERIMENTAL): Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination~1. who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or~2. who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon
- Sof+Velpa+R+Peg-IFN arm (Type: EXPERIMENTAL): Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination

Based on this trial design, predict the completion outcome and termination type (if applicable).